Skip to content

GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks

Kris Kowdley, Virginia Mason Medical Center, Seattle [Photo by Liz Highleyman, hivandhepatitis.com]

Reductions in visceral fat during tesamorelin therapy associated with improvements in key metabolic markers

Chronic hepatitis B infection associated with twice the risk of liver-related death compared to hepatitis C

People with TB and HIV in South Africa face a double stigma

Incidence of hepatitis C re-infection and clearance may be understimated

Untreated HIV infection is associated with higher blood alcohol levels

Treatment switches becoming less common, side-effects still the key reason for switching

Abbott interferon-free HCV combinations show early promise in untreated patients

Boceprevir a useful option for patients who did not respond to earlier course of hepatitis C therapy